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Abstract 
 
Cinnamon (Cinnamomum spp.), an ancient spice, has been explored as a potential for medicinal 
purposes. Despite numerous studies about its potency in overcoming of numerous diseases, the 
potency as anti-cancer would be a challenge. This current article provides a review of the anti-
cancer and chemoprevention potency of cinnamon and its major constituents: cinnamaldehyde, 
cinnamic acid, 2-hydroxycinnamaldehyde, 2-methoxycinnamaldehyde, and eugenol. Comprehensively, 
cinnamon and its constituents exhibit the anti-cancer and cancer prevention activities through 
various mechanisms: (1) anti-proliferation, (2) induction of cell death, (3) anti-angiogenesis, (4) anti-
metastasis, (5) suppression of tumor-promoted inflammation, (6) immunomodulation, and (7) 
modulation of redox homeostasis; both in vitro and in vivo. Moreover, cinnamon also shows the 
synergistic anti-cancer effect with well-known anti-cancer drugs, such as doxorubicin, which support 
its potency to be used as a combination chemotherapeutic (co-chemotherapeutic) agent. However, 
further study should be established to determine the exact target molecule(s) of cinnamon in the 
cancer cells. 
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INTRODUCTION 
 
Cinnamon has been widely used in either the 
East or West parts of the world as a spice for 
thousands of years. Originally from Ceylon (Sri 
Lanka), cinnamon spreads around the world through 
trading and colonization (Barceloux, 2009). The 
genus Cinnamomum is made up of more than 250 
species, which primarily cultivated in Asia and 
Australia. Some of the most valuable and famous 
species are Cinnamomum zeylanicum (Sri 
Lanka/Ceylon cinnamon), Cinnamomum cassia 
(China cinnamon), and Cinnamomum burmanni 
(Indonesia cinnamon). 
Cinnamon bark is the most common part to be 
used from a cinnamon tree. Numerous studies have 
been conducted to reveal the biological activity of 
cinnamon. One of the most well studied is the 
potency of cinnamon as an anti-diabetic agent. As 
reviewed by Ranasinghe, et al. (2012), C. 
zeylanicum showed an anti-diabetic activity in vitro, 
such   as   stimulating   cellular   glucose  uptake   by  
membrane translocation of glucose transporter-4, 
stimulating glucose metabolism and glycogen 
synthesis; and in vivo, including reducing fasting 
blood glucose and increasing circulating insulin 
levels. Another biological activity of cinnamon is the 
gastro-protective effect, which is attributed to 
cinnamon activity as an anti-inflammatory and anti-
ulcer agent (Yu, et al., 2012; Alqasoumi 2012). A 
pharmaceutical company in Indonesia, Dexa Medica, 
steps up the value of cinnamon by using it as the 
active ingredient of their drugs. Dexa Medica has 
formulated the standardized extract of C. burmanni 
into Inlacin® and Redacid® with the indication as 
an anti-diabetic and gastro-protector, respectively.  
Ranasinghe, et al. (2013) provided a 
comprehensive systematic review regarding 
cinnamon biological activities, including a) anti-
microbial and  anti-parasitic activity, b)  lowering  of  
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blood glucose, blood pressure, and serum 
cholesterol, c) antioxidant and free-radical 
scavenging properties, d) inhibition of tau 
aggregation and filament formation (hallmarks of 
Alzheimer’s disease), e) inhibitory effects on osteo-
clastogenesis, f) anti-secretagogue and anti-gastric 
ulcer effects, g) anti-nociceptive and anti-
inflammatory activity, h) wound healing properties 
and i) hepato-protective effects. Yet, in spite of 
numerous research reported the activity of cinnamon 
as an anti-cancer agent, to date there is no 
comprehensive review in this topic. Therefore, here 
we review the recent original research articles 
studying cinnamon and/or its constituent effect on 
various models of cancer. This review article aims to 
provide an overview regarding the activity cinnamon 
and its chemical constituents as an anti-cancer and 
chemopreventive agent. Furthermore, we discuss the 
molecular targets of cinnamon in cancer cells in 
order to provide a deeper and comprehensive 
understanding of cinnamon potency as an anti-
cancer and chemopreventive agent. 
 
CONSTITUENTS OF CINNAMON BARK 
 
The most common method to extract the 
constituent of cinnamon bark is by either water 
extraction or distillation, yielded in aqueous extract 
or essential oil, respectively. Using both methods, 
cinnamaldehyde/ trans-cinnamaldehyde/ cinnamic 
aldehyde remains as the main constituent of 
cinnamon bark. Ding, et al. (2011) analyzed the 
content of cinnamon barks and twigs and found 
cinnamaldehyde as the most abundant marker 
component (average content was 86.25 mg/g), 
followed by eugenol (14.40 mg/g), coumarin (5.79 
mg/g), cinnamyl alcohol (1.13 mg/g), and cinnamic 
acid (0.87 mg/g). 
 In addition to those compounds, they also 
found 2-hydroxyl cinnamaldehyde, cinnamyl 
alcohol, and 2-methoxy cinnamaldehyde in the 
sample. Another study by Kamaliroosta, et al. 
(2012) found that the essential oil of cinnamon barks 
(C. zeylanicum) comprises of cinnamic aldehyde 
(62.09 %), para-methoxycinnamic aldehyde 
(11.56%), alpha-copaene (6.98%), and alpha-
muurolene (4.32%) as the main constituents. In this 
current article, we discuss several unique 
constituents of cinnamon bark that have been studied 
as the anti-cancer and chemopreventive agents, 
which are cinnamaldehyde, cinnamic acid, 2-
hydroxycinnamaldehyde, 2-metho-
xycinnamaldehyde, and eugenol (Fig. 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Chemical   constituents   of    cinnamon   bark   that   have   been  studied   as   the  anticancer  and   
  chemopreventive agent 
Cinnamic acid 
Eugenol 
Cinnamaldehyde 
2-methoxycinnamaldehyde 2-hydroxycinnamaldehyde 
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ANTI-CANCER ACTIVITIES OF 
CINNAMON BARK 
 
Cancer is a disease with multiple 
physiological changes due to the complex genetic 
alteration. A renowned review paper by Hanahan 
and Weinberg in 2011 summarized the 
characteristics of cancer cells as following: (1) 
sustaining proliferative signaling; (2) evading 
growth suppressor; (3) avoiding immune destruction; 
(4) enabling replicative immortality; (5) tumor-
promoting inflammation; (6) activating invasion and 
metastasis; (7) inducing angiogenesis; (8) genome 
instability and mutation; (9) resisting cell death; and 
(10) deregulating cellular energetics (Hanahan and 
Weinberg, 2011). In general, cancer cells are able to 
grow uncontrollably, escaping cell death and 
immune destruction, invade tissues and metastasize, 
induce angiogenesis, promote inflammation in 
surrounding tissues, and has aberrant cell 
metabolism. In addition to those mentioned features, 
scientists also consider redox homeostasis in the 
cancer cells to be a target for cancer therapy. Redox 
homeostasis is the capacity of cells to manage the 
electrochemical potential inside the cells, which 
mostly related to the cells’ oxidative state (Wondrak, 
et al., 2009). Combination chemotherapy (co-
chemotherapy) is also in well-known strategy that 
works by combining two or more anti-cancer or 
chemopreventive agent in order to increase the 
efficacy of cancer therapy and/or alleviate the side 
effect of cancer therapy.  
Researchers have conducted myriad studies 
on the anti-cancer potency of cinnamon bark. The 
summary of anti-cancer activities of extract and/or 
essential oil of cinnamon bark is available in the 
Table 1; while the summary of anti-cancer activities 
of the chemical constituents of cinnamon bark is 
available in the Table 2.  
 
 
Table 1. Anti-cancer activity of cinnamon extract/essential oil 
 
Preparation of 
extract/ 
essential oil 
Physiology/cellular effect  
as anti-cancer 
Molecular event(s) Reference 
aqueous extract of 
C.  cassia (AEC) 
- AEC inhibits melanoma 
progression in vivo  
- AEC inhibits tumor angiogenesis in 
vivo 
- AEC increases the cytolytic activity 
of CD8+ T cells in tumor draining 
lymph nodes.  
 
- Down-regulates the 
level of pro-
angiogenic factors 
(EGF, VEGF-α, TGF-
b, and FGF) 
- Down-regulates the 
level of HIF-1α and 
COX-2  
Kwon, et al. (2009) 
- AEC inhibits tumor cell growth (in 
HeLa, Caco-2, EL4, and Clone M3 
cell lines) in vitro, but not in normal 
cells (primary mouse lymphocyte) 
- AEC inhibits tumor cell growth in 
vivo 
- Down-regulates both 
activity and 
expression level of 
NFκB and AP1 
- Inhibits the 
expression of anti-
apoptotic proteins 
(Bcl-2, BcL-xL and 
survivin) 
Kwon, et al. (2010) 
- AEC inhibits SiHa cervical cancer 
cells growth and migration 
- AEC induces apoptosis in SiHa 
cells 
- Decreases the 
expression of MMP-2 
and HER2 
- Decreases 
mitochondrial 
membrane potential  
Koppikar, et al. (2010) 
- AEC inhibits angiogenesis in 
HUVEC cells and zebrafish embryo 
- Decreases TPA-
induced PKCα and 
PKCγ mRNA 
expression  
Bansode, et al. (2013) 
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- Decreases VEGFR1 
and VEGFR2 mRNA 
expression 
- Inhibits the 
phosphorylation of 
MAPK signaling 
cascade 
aqueous extract of 
Cinnamomum 
Burmannii 
(AEB) 
 
- AEB inhibits the proliferation of 
myeloid cell lines (Jurkat, 
Wurzburg, and U937 cells) 
- AEB induced G2/M arrest in 
myeloid cells 
- Decreases the 
intracellular 
phosphatase activity 
 
Schoene, et al. (2005) 
aqueous extract of 
Cinnamomum 
zeylanicum 
(AEZ) 
 
- AEZ shows higher cytotoxic 
activity compared to commercial 
cinnamaldehyde (at comparable 
concentraton of cinnamaldehyde) 
in various cancer cell lines 
- In the toxic dose, AEZ shows 
significant higher cytotoxicity in 
cancer cells rather than in normal 
cell 
Not determined Singh, et al. (2009) 
Essential oil of 
Cinnamomum 
burmannii 
(EOB) 
 
- EOB shows cytotoxicity and 
induces apoptosis in T47D breast 
cancer cells and HeLa cells 
- EOB shows synergist effect with 
doxorubicin in T47D cells and with 
cisplatin in HeLa cells 
Not determined Anjarsari, et al. (2013) 
Larasati, et al. (2014) 
Ethanol extract of 
cinnamon (EC) 
- EC inhibits the proliferation of HT-
29 colon cancer cells, but not 
CCD-112CoN normal colon cells 
 
- Decreases the 
production of PGE2 
- Decreases the 
expression of 
COX-2 
Lee, et al. (2006) 
AP1: activator protein 1; Bcl-2: B-cell lymphoma 2; Bcl-xL: B-cell lymphoma-extra large; COX-2: cyclooxygenase 2; EGF: epidermal growth 
factor; FGF: fibroblast growth factor; HER2: human epidermal growth factor receptor 2; HUVEC: human umbilical vein endothelial cells; 
MAPK: mitogen-activated protein kinase; MMP-2: matrix metalloproteinase-2; mRNA: messenger ribonucleic acid; NFκB: nuclear factor 
kappa B; PGE2: prostaglandin E2; PKCα: protein kinase C-α; PKCγ: protein kinase C-γ; TGF-β: transforming growth factor-β; VEGF-α: 
vascular endothelial growth factor-α; VEGFR1: vascular endothelial growth factor receptor 1; VEGFR2: vascular endothelial growth factor 
receptor 2. 
 
 
Table 2. Anti-cancer activity of the constituents of cinnamon bark 
 
Compound Physiology/cellular effect  
as anti-cancer 
Molecular event(s) Reference 
Cinnamaldehyde / 
trans-
cinnamaldehyde/ 
cinnamic aldehyde/  
(CA) 
- CA inhibits the proliferation and 
induces apoptosis in HL60 pro-
myelocytic leukemia cells 
- Increases ROS 
intracellular 
Ka, et al. (2003) 
- CA exhibits cytotoxicity in Jurkat 
and U397 leukemia cells, but not in 
normal T cells and macrophages 
- CA induces G2/M arrest in Jurkat 
and U397 leukemia cells 
- Not determined Fang, et al. (2004) 
- CA suppresses the proliferation of 
human metastatic melanoma cell 
lines (A375, G361, LOX) with G1 
cell cycle arrest in vitro 
- CA inhibits tumor progression in vivo 
- Increases intracellular 
ROS 
- Up-regulates HMOX1, 
SRXN1, TXNRD1, 
CDKN1A  
Cabello, et al. (2009) 
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- CA treatment at low micromolar 
concentrations up-regulates 
oxidative stress response gene 
expression  in  A375  melanoma  
cells  
- Inhibits of NFκB 
transcriptional activity 
and TNFα-induced IL-8 
production  
- CA induces apoptosis in K562 
leukemia cells 
- CA exhibits synergist cytotoxicity 
with cytokine-induced killer (CIK) 
cells  
 
- Up-regulates Fas 
expression 
- Decreases 
mitochondrial 
transmembrane 
potential  
Zhang, et al. (2010) 
- CA inhibits the proliferation and 
induces apoptosis in HCT116 colon 
cancer and MCF-7 breast cancer 
cells 
- CA induces G2/M arrest in HCT116 
cells 
- Inhibits thioredoxin 
reductase enzymatic 
activity 
- Induces Nrf2 activity 
Chew, et al. (2010) 
- CA exhibits cytotoxicity in colon 
cancer cells 
- Pre-treatment with CA attenuates 
H2O2-induced genotoxicity in colon 
cancer cells 
 
- Up-regulates the Nrf2 
activity 
- Up-regulates heme 
oxygenase 1 (HO-1) 
and γ-glutamylcysteine 
synthetase (γ-GCS, 
catalytic subunit)  
- Up-regulates cellular 
glutathione level  
Wondrak, et al. 
(2010) 
 
- CA induces apoptosis and G2/M 
arrest in HCT116 cells 
- CA induces tubulin aggregation 
 
- Down-regulates Cdk1 
and cdc25 
- Up-regulates the level 
of cyclin B 
Nagle, et al. (2012) 
- CA inhibits the proliferation and 
induces apoptosis in HepG2 and 
Hep3B hepatoma cells 
 
- Decreases the 
expression of cyclin D1, 
PCNA, and Bcl-2 
- Induces the expression 
of p27 and p21 
- Activates caspase-3 
- Inhibits JAK2–
STAT3/STAT5 signaling 
pathway 
Chuang, et al. (2012) 
- CA shows higher cytotoxicity than 
cisplatin in C666-1 human 
nasopharyngeal carcinoma (NPC) 
cells  
- CA shows synergist anti-proliferative 
effect with cisplatin 
- Induces 
phosphorylation of 
histone H2AX 
- Induces activation of 
caspase-3/7 
 
Daker, et al. (2013) 
 
 
Cinnamic acid 
(CINN) 
- CINN inhibits the invasiveness of 
A549 lung adenocarcinoma cells 
without significant effect on the 
adhesive activity of cells  
- cis-cinnamic acid shows higher 
activity than trans-cinnamic acid 
- Inhibits the activity of 
MMP-2 and MMP-9 
 
Yen, et al. (2011) 
- CINN pre-treatment reduces 
cyclophosphamide-induced 
myelosuppression and oxidative 
stress in bone marrow 
 
- Reduces lipid 
peroxidation 
- Increases the activity of 
antioxidant enzymes 
(superoxide dismutase, 
catalase and 
Patra, et al. (2012) 
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glutathione-S-
transferase) 
- CINN inhibits the invasiveness of 
A549 lung adenocarcinoma cells  
 
- Inhibits the activity of 
MMP-2 and MMP-9 
- Increases the levels of 
PAI-2 to suppress uPA 
activity  
- Supresses NFκB and 
AP-1  
Tsai, et al. (2013) 
- CINN inhibits the proliferation of 
lung cancer stem cells 
- CINN induces G1 arrest and 
apoptosis in lung cancer stem cells 
- CINN increases the sensitivity of 
lung cancer stem cells toward 
cisplatin and paclitaxel 
- CINN promotes differentiation and 
reduces the invasive ability of lung 
cancer stem cells  
- Down-regulates Bcl-2 
and survivin 
- Up-regulates Bax 
Huang, et al. (2012) 
- CINN induces cytotoxicity and 
apoptosis in human melanoma cell 
line (HT-144)  
 
- Increases the activation 
of caspase-3 and 
expression of Bax 
- Decreases the 
expression of Bcl-2 
de Oliveira Niero and 
Machado-Santelli 
(2013) 
2-
hydroxycinnamalde
hyde 
(2-HCA) 
- 2-HCA induces apoptosis in SW620 
colon cancer cells  
 
- 2-HCA binds to 5 
subunits of proteasome 
complex and inhibits 
the activity of 
proteasome 
- Induces ER stress 
- Decreases 
mitochondrial 
membrane potential 
Hong, et al. (2007) 
- 2-HCA inhibits the growth and 
induces apoptosis in SW 620 human 
colon cancer cell  
 
- Inhibits AP-1 
transcriptional activity 
and DNA binding 
activity  
- Inhibits c-Jun and c-Fos 
expression 
- Increases caspase-3 and 
decreases Bcl-2 
Lee, et al. (2007) 
- 2-HCA inhibits oral cancer growth in 
vitro and in vivo  
- 2-HCA induces apoptosis and cell 
cycle arrest in G2/M phase 
- Increases the levels of 
cleaved PARP and 
caspase-3  
 
Kim, et al. (2010) 
- 2-HCA inhibits the proliferation of 
HCT116 colon cancer and MCF-7 
breast cancer cells 
- Inhibits thioredoxin 
reductase enzymatic 
activity 
Chew, et al. (2010) 
- 2-HCA inhibits breast cancer cell 
migration without affecting viability  
- 2-HCA inhibits EGF-induced EMT in 
breast cancer cells 
- 2-HCA inhibits lung metastasis and 
micromestastasis in vivo 
 
- Increases E-cadherin 
transcription 
- Suppresses the protein 
level of Snail 
- Induces KLF17 
expression 
- Suppresses SP-1 and ID-
1 expression  
 
Ismail, et al. (2013) 
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- 2-HCA inhibits the proliferation of 
HCT116 colon cancer cells 
- 2-HCA suppressed tumor growth in 
vivo 
- Inhibits Wnt/β-catenin 
transcriptional activity 
- Decreases the mRNA 
level of CCND1, CMYC, 
MMP7, PLAU, XIN2, 
NKD1, and DKK1  
Lee, et al. (2013) 
2-
methoxycinnamalde
hyde  
(2-MCA)  
 
- 2-MCA inhibits the proliferation of 
HCT116 colon cancer and MCF-7 
breast cancer cells  
- Not determined Chew, et al. (2010) 
- 2-MCA inhibits tumor growth via 
inhibition of angiogenesis in vivo 
- 2-MCA inhibits the maturation of 
tumor vasculature  
- Inhibits the 
phosphorylation of Tie2  
 
Yamakawa, et al. 
(2011) 
Eugenol 
- Eugenol showed a dose-dependent 
selective cytotoxicity toward HeLa 
cells in comparison to normal cells 
- Eugenol exhibits synergist anti-
cancer effect with gemcitabine in 
HeLa cells 
- downregulation of Bcl-2, 
COX-2, and IL-1β 
 
Hussain, et al. (2011) 
- Eugenol exhibits cytotoxicity and 
induces apoptosis in colon cancer 
cells 
 
- Depletes MMP 
- Generates ROS 
- Activates PARP, p53 and 
caspase-3  
Jaganathan, et al. 
(2011) 
- Eugenol significantly reduces the 
incidence of MNNG-induced gastric 
tumours 
 
- Suppresses of NFκB 
activation 
- Down-regulates NF-κB 
target genes (cyclin D1, 
Cyclin B, PCNA, and 
Gadd45) 
Manikandan et al. 
(2011) 
- Eugenol shows cytotoxicity in breast 
cancer cells and less toxic in non-
neoplastic breast epithelial cells  
- Eugenol induces apoptosis in breast 
cancer cells 
- Eugenol inhibits tumor growth of 
breast tumor in vivo 
 
- Inhibits the expression 
of p65 NFκB, β-catenin, 
cyclin D1, survivin, and 
E2F1. 
- Activates pro-apoptosis 
protein: caspase-3, 
caspase-1, cytochrome c, 
caspase-9 
- Up-regulates p21 
 
Al-Sharif, et al. (2013) 
AP1: activator protein 1; Bcl-2: B-cell lymphoma 2; Bax: Bcl-2 Associated X; COX-2: cyclooxygenase 2; CCND1: cyclin D1 (gene); Cdk1: 
cyclin dependent kinase 1; CDKN1A: cyclin-dependent kinase inhibitor 1A (gene); DKK1: Dickkopf-related protein 1; DNA: 
deoxyribonucleic acid; EGF: epidermal growth factor; EMT: epithelial-mesenchymal transition; ER: endoplasmic reticulum; E2F1: E2 factor-
transcription factor 1; GADD45: growth arrest and DNA-damage-inducible protein 45 alpha; γ-GCS: γ-glutamylcysteine synthetase; HO-
1: heme oxygenase 1 (protein); HMOX1: heme oxygenase-1 (gene); H2O2: hydrogen peroxide; Id-1: inhibitor of differentiation/DNA 
binding; IL-8: interleukin 8; IL-1β: interleukin 1β; JAK: Janus tyrosine Kinase; KLF17: Kruppel Like Factor 17; MMP-2: matrix 
metalloproteinase-2; MMP-9: matrix metalloproteinase-9; MMP7: matrix metalloproteinase-7; MNNG: N-methyl-N
′
-nitro-N-
nitrosoguanidine; NKD: naked cuticle homolog 1;  NFκB: nuclear factor kappa B; Nrf2: nuclear factor erythroid 2 (NFE2)-related factor 2; 
PAI2: plasminogen activator inhibitor-2; PARP: poly (ADP-ribose) polymerase; PCNA: proliferating cell nuclear antigen; PLAU: plasminogen 
activator, urokinase; ROS: reactive oxygen species; SRXN1: sulfiredoxin 1 homolog; STAT: Signal Transducer and Activator of 
Transcription; Sp1: specificity protein 1; TNFα: tumor necrosis factor α; TXNRD1: thioredoxin reductase 1; uPA: urokinase-type 
plasminogen activator; VEGFR2: vascular endothelial growth factor receptor 2. 
 
ANTI-PROLIFERATIVE AND PRO-
APOPTOSIS 
The most well-known and traditional anti-
cancer drugs act as tumor cell growth suppressor 
(anti-proliferative) and cell death-inducer (pro-
apoptosis). The activity of cinnamon bark and/or its 
constituents as the anti-proliferative and pro-
apoptosis are presented below. 
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Cinnamon extract/essential oil 
Aqueous extract of C. cassia (AEC) exhibits 
an anti-proliferative effect in vitro and in vivo in 
various models of cancer, such as melanoma, 
cervical cancer, and colon cancer (Kwon, et al., 
2009; Kwon, et al., 2010; Koppikar, et al., 2010). 
Koppikar, et al. (2010) found that AEC increases 
intracellular levels of calcium, leads to perturbation 
of mitochondrial membrane potential, which 
ultimately induces apoptosis in SiHa cervical cancer 
cells. Another study by Kwon, et al. (2010) found 
that AEC also suppresses the expression of anti-
apoptotic proteins (e.g., Bcl-2, BcL-xL, and 
survivin) by down-regulating the activity and 
expression level of NFκB and AP1 proteins. 
Another species of cinnamon, C. burmannii, 
also exhibits anti-cancer potency. Schoene, et al. 
(2005) reported that the aqueous extract of C. 
burmannii (AEB) inhibits the proliferation of some 
myeloid cell lines: Jurkat, Wurzburg, and U937 
cells). AEB decreases the intracellular phosphatase 
activity that later induces cell cycle arrest in G2/M 
phase. In addition, the essential oil of C. burmannii 
shows cytotoxicity and induces apoptosis in T47D 
breast cancer cells (Anjarsari, et al., 2013). 
Interestingly, cinnamon bark shows selective 
anti-proliferative effect towards cancerous cells 
rather than normal (non-cancerous) cells. Lee, et al. 
(2006) reported that the extract of cinnamon inhibits 
the proliferation of HT-29 colon cancer cells, but not 
CCD-112CoN normal colon cells. A similar result 
was reported by Kwon, et al. (2010); AEC inhibits 
tumor cell growth (in HeLa, Caco-2, EL4, and Clone 
M3 cell lines) in vitro, but not in normal cells 
(primary mouse lymphocyte). Moreover, Singh, et 
al. (2009) reported that the aqueous extract of C. 
zeylanicum (AEZ) shows significant higher 
cytotoxicity in cancer cells rather than in the normal 
cells. This selectivity feature is very important for 
the anti-cancer drugs that hopefully the drugs have 
minimum side effect for the clinical therapy. 
 
Cinnamaldehyde 
Cinnamaldehyde exhibits anti-proliferative 
activity in various cancer cells, including leukemia 
melanoma, colon cancer, nasopharyngeal carcinoma, 
breast cancer, and hepatoma in vitro (Ka, et al., 
2003; Fang, et al., 2004; Cabello, et al., 2009; Chew, 
et al., 2010; Wondrak, et al., 2010; Chuang, et al., 
2012; Daker, et al., 2013). Moreover, 
cinnamaldehyde also suppresses tumor cell 
progression in vivo in the mouse model of cancer 
(Cabello, et al., 2009). 
Suppression of cancer cell growth can be 
attributed to the inhibition of cell division (cell 
cycle) and/or induction of cell death. 
Cinnamaldehyde induces G1 cell cycle ar,rest in 
melanoma cells (Cabello, et al., 2009). However, 
other studies found that cinnamaldehyde induces 
G2/M arrest in Jurkat and U397 leukemia cells; as 
well as HCT116 colon cancer cells (Fang, et al., 
2004;, Chew, et al., 2010; Nagle, et al., 2012). 
Nagle, et al. (2012) reported several molecular 
events by which cinnamaldehyde induces G2/M 
arrest. Cinnamaldehyde down-regulates protein 
Cdk1 and cdc25, which are the important proteins 
for  G2/M progression. Cyclin B, an important 
protein that should be diminished during G2/M 
progression, was sustained by cinnamaldehyde. 
Moreover, cinnamaldehyde induces tubulin 
aggregation; hence the cells in G2/M phase can not 
further divide themselves. 
In addition to the induction of cell cycle 
arrest, cinnamaldehyde induces apoptosis in 
leukemia, colon cancer, breast cancer, hepatoma, 
and   human nasopharyngeal carcinoma (NPC) cells 
(Ka, et al., 2003; Zhang, et al., 2010; Chew, et al., 
2010; Chuang, et al., 2012; Daker, et al., 2013). 
Several mechanisms contribute to the apoptosis 
effect of cinnamaldehyde, such as generation of 
intracellular ROS (Ka, et al., 2003), up-regulation of 
cell death surface receptor Fas (Zhang, et al., 2010), 
and modulation of pro- and anti-apoptosis proteins 
(Chuang, et al., 2012; Daker, et al., 2013). 
 
Cinnamic acid 
Cinnamic acid exhibits cytotoxicity and 
induces apoptosis in HT-144 human melanoma 
cells (de Oliveira Niero and Machado-Santelli, 
2013). Cinnamic acid up-regulates the activity of 
caspase-3 and expression of Bax, the pro-apoptotic 
proteins; while decreasing the expression of Bcl-2, 
an anti-apoptotic protein (de Oliveira Niero and 
Machado-Santelli, 2013). Interestingly, cinnamic 
acid also exhibits anti-cancer activity in the cancer 
stem cells. Huang, et al. (2012) examined the effect 
of cinnamic acid in lung cancer stem cells. 
Cinnamic acid inhibits the proliferation as well as 
induces apoptosis and G1 arrest in the lung cancer 
stem cells. 
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2-hydroxycinnamaldehyde (2-HCA) 
2- HCA shows the anti-proliferative activity 
in colon cancer and oral cancer; as well as induces 
apoptosis in those cells (Hong, et al., 2007; Lee, et 
al., 2007; Kim, et al., 2010). Lee, et al. (2013) also 
showed that 2-HCA inhibits tumor progression in 
vivo. Hong, et al. (2007) found that 2-
hydroxycinnamaldehyde decreases mitochondrial 
membrane potential, resulting in cell apoptosis. Lee, 
et al. (2007) showed that 2-hydroxycinnamaldehyde 
modulates the pro- and anti-apoptotic protein levels, 
such as caspase-3 and Bcl-2. In addition to 
apoptosis, 2-HCA induces cell cycle arrest in G2/M 
phase (Kim, et al., 2010). 2- HCA also inhibits the 
transcriptional and DNA binding activity of AP-1, a 
transcriptional factor important for cancer cell 
growth (Lee, et al., 2007). 
2- HCA is the only constituent of cinnamon 
bark that has been studied for its direct protein target 
in cancer cells.  Hong, et al. (2007) performed a 
pull-down assay and found that 5 subunits of 
proteasome complex interacted physically with 2-
hydroxycinnamaldehyde. This interaction inhibits 
the activity of proteasome, resulting in various 
perturbations inside the cancer cells, leading to 
apoptosis. Even though not yet elucidating the direct 
binding site, Hong and colleague suggests that 2-
hydroxycinnamaldehyde is an effective proteasome 
inhibitor by inactivating multiple catalytic activities 
of proteasome. Another possible target of 2-HCA is 
the Wnt/β-catenin pathway. Lee, et al. (2013) 
showed that 2-HCA inhibits the transcriptional 
activity of Wnt/β-catenin. This inhibition results in 
down-regulation of various gene targets of Wnt/β-
catenin signaling, such as CCND1, CMYC, MMP7, 
PLAU, XIN2, NKD1, and DKK1, which are the 
proteins that play role in cell proliferation, survival, 
and motility. 
 
2-methoxycinnamaldehyde (2-MCA)  
2-MCA inhibits the proliferation of HCT116 
colon cancer cells (Chew, et al., 2010). However, 
further study is needed to elucidate its exact 
molecular mechanism. 
 
Eugenol 
Although not only found in cinnamon bark, 
eugenol is one of the major constituents of 
cinnamon. An interesting feature of eugenol is that it  
selectively toxic to cancer cells, but less toxic in 
normal cells. Hussain, et al. (2011) reported that 
eugenol exhibits cytotoxicity in HeLa cervical 
cancer cells, but not in normal cells. Another study 
by Al-Sharif, et al. (2013) showed that eugenol is 
more toxic in the breast cancer cells rather than in 
non-neoplastic breast epithelial cells. Eugenol 
induces apoptosis in cervical cancer, colon cancer, 
and breast cancer cells in vitro (Hussain, et al., 2011; 
Jaganathan, et al., 2011; Al-Sharif, et al., 2013). 
Eugenol also exhibits anti-tumor activity in vivo, in 
rats developing MNNG-induced gastric tumors 
(Manikandan, et al., 2011) and breast cancer-
xenografted mice (Al-Sharif, et al., 2013). 
At the molecular level, eugenol activates the 
pro-apoptotic proteins, such as PARP, caspase-3, 
caspase-1, and caspase-9; as well as up-regulates cell 
cycle regulator proteins p53 and p21 (Jaganathan, et 
al., 2011; Al-Sharif, et al., 2013). Eugenol also 
suppresses the expression and activation of NFκB, 
resulting in down-regulation of NF-κB target genes 
(cyclin D1, Cyclin B, PCNA, Gadd45) 
(Manikandan, et al., 2011). 
 
ANGIOGENESIS 
To supply the nutrition and oxygen for their 
growth, cancer cells form blood vessels in a process 
called angiogenesis. Hypoxia, a condition in which 
cancer cells lack of oxygen, plays a key role in 
angiogenesis; which then activates VEGF signaling 
as the important mediator of angiogenesis (Hanahan 
and Weinberg, 2011). The activity of cinnamon bark 
and/or its constituents as an anti-angiogenic agent is 
discussed below. 
 
Cinnamon extract/essential oil 
Kwon, et al. (2009) reported that AEC 
inhibits tumor angiogenesis in vivo and down-
regulates the level of pro-angiogenic factors (e.g., 
EGF, VEGF-a, TGF-b, and FGF). They also found 
that AEC decreases the level of HIF-1α, a 
transcription factor that is active in hypoxia 
condition and promote tumor angiogenesis. Another 
study by Bansode, et al. (2013) reported that AEC 
inhibits the formation of blood vessels in HUVEC 
cells and zebrafish embryo. More over, Bansode, et 
al. showed that AEC inhibits the expression of PKC 
and inactivates MAPK/Akt signaling, which turns 
out decreases the expression of VEGFR. 
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2-methoxycinnamaldehyde (2-MCA)  
Yamakawa, et al. (2011) showed that 2-MCA 
suppresses tumor growth in vivo by inhibiting 
angiogenesis. Moreover, 2-MCA inhibits the 
maturation of blood vessels in the tumor (tumor 
vasculature). At the molecular level, 2-MCA inhibits 
the phosphorylation of Tie2, a vascular growth 
factor that is overexpressed in various tumors and 
induces angiogenesis. 
 
METASTASIS 
In the onset of cancer, cancer cells starts to 
grow in the certain part of the body and become 
much more harmful once they spread to the other 
parts of the body, in a process called metastasis 
(Hanahan and Weinberg, 2011). The metastasis 
process consists of two steps: invasion and 
migration. Matrix-metalloproteinase protein (MMP) 
family mediates these processes by degrading the 
extracellular matrix (ECM) proteins of the cells, 
make it possible for cancer cells to sneak out their 
original place and migrate to other parts of the body 
(Deryugina and Quigley, 2006). The activity of 
cinnamon bark and/or its constituents as an anti-
metastatic agent is presented below. 
 
Cinnamon extract/essential oil 
Koppikar, et al. (2010) found that AEC 
decreases the expression of MMP-2, both the mRNA 
and protein level, in SiHa cervical cancer cells. 
Furthermore, AEC also down-regulates the level of 
HER-2 protein, an important marker in cervical 
cancer related to the invasion capacity of the tumor 
cells. 
 
Cinnamic acid 
Yen, et al. (2011) and Tsai, et al. (2013) 
reported that cinnamic acid inhibits the invasive 
ability of A549 lung adenocarcinoma cells. 
Cinnamic acid decreases the mRNA level and 
activity of MMP-2 and MMP-9, as well as 
suppresses the activity of NFκB and AP-1 (Tsai, et 
al., 2013). Moreover, cinnamic acid also reduces the 
invasive ability of lung cancer stem cells (Huang, et 
al., 2013). Interestingly, the cis form of cinnamic 
acid exhibits a better anti-metastatic activity 
compared to the trans-cinnamic acid (Yen, et al., 
2011). 
 
 
2-hydroxycinnamaldehyde (2-HCA) 
Ismail, et al. (2013) reported the potency of 2-
HCA as an anti-metastatic agent. They showed that 
sub-toxic dose of 2-HCA inhibits breast cancer cell 
migration in vitro. 2-HCA also inhibits epidermal 
growth factor (EGF)-induced epithelial-
mesenchymal transition (EMT) in breast cancer 
cells. In vivo, 2-HCA is able to inhibit lung 
metastasis and suppress micro-metastasis. 
At the molecular level, 2-HCA suppresses the 
protein level of Snail, a transcriptional repressor of 
E-cadherin. Therefore, the transcription of E-
cadherin, a protein important protein for cell-cell 
adhesion, is increased; resulting in the stronger cell-
cell integrity. Moreover, 2-HCA induces KLF17 
expression. KLF17 is a repressor of Id-1, a protein 
that increases the invasion of breast cancer cells. 
Consequently, the 2-HCA decreases the expression 
of Id-1 and inhibits breast cancer invasion. 
 
TUMOR-PROMOTED INFLAMMATION 
It was thought that the immune cells found in 
the cancerous tissues aim to eradicate cancer cells 
inside the tissue. It turns out that those immune cells 
promote inflammation within the tumor. That 
inflammation then provides the tumor 
microenvironment with various bioactive molecules, 
including growth factors and pro-angiogenic factors 
(Hanahan and Weinberg, 2011). Inflammation also 
plays an important role in tumor initiation. 
Therefore, an anti-inflammatory agent has the 
potency to be developed as an anti-cancer and 
chemopreventive agent. The activity of cinnamon 
bark and/or its constituents as an anti-inflammatory 
agent is discussed below. 
 
Cinnamon extract/essential oil 
Kwon, et al. (2010) reported that AEC down-
regulates the activity of NFκB, an important protein 
for inflammation. In addition, Lee, et al. (2006) 
reported that the ethanol extract of cinnamon 
decreases the production of PGE2 and the expression 
of COX-2, two important mediators of 
inflammation. 
 
Cinnamaldehyde 
Several studies showed the anti-inflammatory 
activity  of  cinnamaldehyde  in  models  other   than  
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cancer cells. Kim, et al. (2007) showed that 
cinnamaldehyde inhibits the activation of NFκB via 
three signal transduction pathways: NIK/IKK, ERK, 
and p38 MAPK. Cinnamaldehyde also blocks IL-1β-
induced PGE2 production in the mouse cerebral 
microvascular endothelial cell (Ma, et al., 2008) and 
mouse macrophage RAW264.7 cells (Zhang, et al., 
2012). Zhang, et al. also reported that 
cinnamaldehyde suppresses the expression of PGE-
synthase-1 (mPGES-1), an important inducer of 
PGE2 production. 
 
IMMUNOMODULATION 
The immune system is very important for 
cancer elimination as it can help to fight cancer cells 
with no toxicity to normal tissue. However, the 
problem arises as the eternal mutation in cancer cells 
gives them the ability to evade the immune system. 
Therefore, scientists develop some strategies to 
utilize the components of immune system as cancer 
therapy, such as by directly targeting specific 
antigens expressed by cancer cells or targeting the 
immune system in the tumor microenvironment, 
such as cytokines, suppressors of Treg or MDSC 
activity, or antibodies that modulate T-cell activity 
(Finn, et al., 2012). 
Cinnamon extract is able to modulate the 
activity of T cells, the cytotoxic immune cells. AEC 
increases the increased the anti-tumor activities of 
CD8+ T cells in tumor draining-lymph nodes 
(Kwon, et al., 2009). Kwon and colleagues found 
that AEC increases the cytolytic molecules (IFN-ϒ 
and TNF-α) expressed in the surface of CD8+ T 
cells. Furthermore, AEC increases the killing 
activity of CD8+ T cells toward cancer cells. 
 
REDOX HOMEOSTASIS IN CANCER 
CELLS 
Redox homeostasis plays an important yet 
complex role in the normal and cancer cells. The 
main component of redox homeostasis is the reactive 
oxygen species (ROS), which at the low level serves 
as a mediator of signal transduction; while at the 
high level disrupts various cell components, leading 
to excessive mutations and/or cell death (Sosa, et al., 
2013). Therefore, the level of intracellular ROS must 
be regulated through a reliable redox system, which 
comprises of various enzymatic systems, such as 
glutathione redox system, thioredoxin system, and 
Nrf2/Keap1-ARE pathway (Wondrak, et al., 2009). 
Cinnamaldehyde 
Ka, et al. (2003) reported that 
cinnamaldehyde increases intracellular in HL60 pro-
myelocytic leukemia cells. Another study by 
Cabello, et al. (2009) also showed that 
cinnamaldehyde increases the intracelullar reactive 
oxygen species (ROS) that leads to cancer cell death. 
However, at the sub-toxic dose, cinnamaldehyde up-
regulates the oxidative stress response genes such as 
heme oxygenase-1 (HMOX1), sulfiredoxin 1 
homolog (SRXN1), thioredoxin reductase 1 
(TXNRD1). Moreover, Wondrak. et al. (2010) also 
reported a similar result. Wondrak and colleagues 
found that cinnamaldehyde is a potent activator of 
Nrf2 transciption. Sub-toxic concentration of 
cinnamaldehyde (concentration range 6–10 μM) 
strongly induced the transcription of Nrf2. 
 
Cinnamic acid 
Patra, et al. (2012) showed the activity of 
cinnamic acid as an antioxidant. Cinnamic acid 
increases the activity of antioxidant enzymes, such 
as superoxide dismutase, catalase and glutathione-S-
transferase, as well as reduces lipid peroxidation.  
 
2-hydroxycinnamaldehyde (2-HCA) 
Chew, et al. (2010) reported that 2-HCA 
inhibits thioredoxin reductase enzymatic activity. 
 
Eugenol 
Jaganathan, et al. (2011) reported that eugenol 
treatment elevates the intracellular ROS levels after 
12 h and sustained until 48 h. Pre-treatment of 
cancer cells with n-acetyl-cysteine (NAC), a 
powerful antioxidant, blocked eugenol-induced 
apoptosis. This result suggests that ROS is a key 
player in eugenol activity as an anti-cancer agent. 
 
CO-CHEMOTHERAPY 
Combination chemotherapy (co-
chemotherapy) is a strategy to increase the 
effectiveness of anti-cancer therapy by combining 
two or more anti-cancer agents. In addition, co-
chemotherapy also aims to reduce the side effects of 
a strong anti-cancer drug. 
 
Cinnamon extract/essential oil 
Anjarsari, et al. (2013) found that the 
essential oil of C. burmannii (EOB) exhibits 
synergistic cytotoxic effect with doxorubicin in 
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T47D breast cancer cells. This essential oil of EOB 
also performs synergist effect with cisplatin to 
induce cell cycle arrest and apoptosis in HeLa cells 
(Larasati, et al., 2014). This synergist activity is 
expected to lower the dose of doxorubicin in cancer 
clinical therapy. 
 
Cinnamaldehyde 
Daker, et al. (2013) reported that 
cinnamaldehyde exhibits higher cytotoxicity than 
cisplatin in C666-1 human nasopharyngeal 
carcinoma (NPC) cells. However, cinnamaldehyde 
also shows a synergist anti-cancer effect when 
combined with cisplatin. Interestingly, 
cinnamaldehyde also exhibits synergist cytotoxicity 
with cytokine-induced killer (CIK) cells toward 
K562 leukemia cells (Zhang, et al., 2010). The CIK 
cells resemble bone marrow transplantation that is 
usually performed in leukemia patients. Therefore, 
Zhang, et al. suggest that cinnamaldehyde is 
compatible to be used even in the leukemia patient 
with former bone marrow transplantation. 
 
Cinnamic acid 
Patra, et al. (2012) reported that cinnamic 
acid pre-treatment protects bone marrow and hepatic 
cells from cyclophosphamide-induced oxidative 
stress. This activity of cinnamic acid occurs as it 
induces the activity of antioxidant enzymes, such as 
superoxide dismutase, catalase, and glutathione-S-
transferase in the liver and bone marrow of mice, 
which counter the oxidative stress caused by 
cyclophosphamide. 
 
FUTURE PROSPECT AND STRATEGY 
 
After a thorough literature study, we found 
that the cinnamon and its constituents exhibit anti-
cancer activities through various mechanisms, 
including anti-proliferation, pro-apoptosis, anti-
angiogenesis, anti-metastasis, inhibition of tumor-
induced inflammatory, immunomodulation, 
modulation of redox homeostasis, and combination 
chemotherapy. Astonishingly, despite its extensive 
anti-cancer mechanism, cinnamon selectively toxic 
to the cancer cells rather than normal cells (Lee, et 
al., 2006; Kwon, et al., 2010; Singh, et al., 2009); 
which is an important feature for the development of 
anti-cancer agents with less side effect. However, in 
spite of the diverse molecular anti-cancer 
mechanisms of cinnamon constituents have been 
reported, only 2-hydroxycinnamaldehyde was shown 
to have direct protein target(s) by Hong, et al. 
(2007). In this time of molecular targeted therapy, 
we need to elucidate more the direct target(s) of 
cinnamon constituents by using advanced 
biomedical and medicinal chemistry approach in 
order to pinpoint the exact anti-cancer mechanism of 
those compounds. 
It is also interesting to note that compounds in 
the cinnamon exhibit the different effect on the cell 
redox homeostasis. Eugenol and 2-
hydroxycinnamaldehyde were reported to act as pro-
oxidant agents that increase the level of intracellular 
ROS and inhibit the cellular antioxidant enzymes 
(Chew, et al., 2010; Jaganathan, et al., 2011).  
Cinnamic acid was reported as an antioxidant agent 
(Patra, et al., 2012); while cinnamaldehyde was 
reported to promote the generation of intracellular 
ROS, but also induce the activation of Nrf2 pathway 
(Ka, et al., 2003; Cabello, et al., 2009; Wondrak, et 
al., 2010). An important factor to be noticed is the 
dose used in those studies. Wondrak, et al. (2010) 
used a relatively low dose of cinnamaldehyde (6–10 
μM) to induce the activation of Nrf2, which 
practically did not show the toxic effect to the cancer 
cells. On the other hand, Ka, et al. (2003) found that 
the IC50 value of cinnamaldehyde in HL60 cells is 
30.7 μM; while Cabello, et al. (2009) showed that 
cinnamaldehyde 25 μM exhibits cytotoxicity in the 
melanoma cells of >90%. These findings suggest 
that cinnamaldehyde exhibits bi-phasic activity in 
redox homeostasis of the cells: at low dose, 
cinnamaldehyde triggers the activation of oxidative 
stress response system, such as Nrf2; while at the 
high dose, cinnamaldehyde boosts the intracellular 
ROS level as one of its anti-cancer mechanism. 
Whether cinnamon and its constituents 
possess the anti- or pro-oxidant activities is 
important to be acknowledged with care. There are 
developing evidence showed that antioxidant favors 
tumor growth. One of the important examples is 
Nrf2 pathway, the major arranger for various 
enzymes that protect the cells from oxidative stress 
(Kansanen, et al., 2013). While conventional studies 
believe that Nrf2 pathway is important to protect the 
normal cells from being cancerous; current 
developing studies reported that Nrf2 might play an 
important role in cancer chemoresistance and 
enhancing cancer cell growth (Shibata, et al., 2008; 
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Homma, et al., 2009). As reviewed by Kansanen, et 
al. (2013), the Nrf2 activators are suitable to be used 
as in cancer prevention; while the Nrf2 inhibitors are 
suitable to be used in cancer therapy. Therefore, the 
low dose cinnamaldehyde is appropriate to be used 
in cancer prevention; while the higher dose is needed 
for its use as the anti-cancer therapy. Considering 
this topic, the cinnamon extract, which contains 
various substances in moderate dosage, is more 
suitable to be used as a chemopreventive agent. 
Meanwhile, the pure chemical constituents of 
cinnamon; such as cinnamaldehyde, cinnamic acid, 
2-hydroxycinnamaldehyde, 2-metho-
xycinnamaldehyde (2-MCA), and eugenol, are 
potential to be developed as the anti-cancer agents. 
 
CONCLUSION 
 
Altogether, cinnamon and its constituent 
demonstrate potency to be used as the anti-cancer 
and chemopreventive agents. Nevertheless, further 
study needs to be conducted to determine the exact 
molecular target(s) of cinnamon constituents. 
Finally, a meta-analysis review with more data and 
statistical analysis would help to reveal the potency 
of cinnamon to the greater extent. 
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